JP2009538824A - 精神疾患及び障害治療用アミリン及びアミリンアゴニスト - Google Patents

精神疾患及び障害治療用アミリン及びアミリンアゴニスト Download PDF

Info

Publication number
JP2009538824A
JP2009538824A JP2009502755A JP2009502755A JP2009538824A JP 2009538824 A JP2009538824 A JP 2009538824A JP 2009502755 A JP2009502755 A JP 2009502755A JP 2009502755 A JP2009502755 A JP 2009502755A JP 2009538824 A JP2009538824 A JP 2009538824A
Authority
JP
Japan
Prior art keywords
amylin
seq
xaa
disorder
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009502755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538824A5 (cg-RX-API-DMAC7.html
Inventor
ケビン・ディ・ロージェロ
マイケル・ハンリー
クリスティン・マック
デイビッド・ジー・パークス
アンドリュー・エイ・ヤング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/012601 external-priority patent/WO2006105527A2/en
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of JP2009538824A publication Critical patent/JP2009538824A/ja
Publication of JP2009538824A5 publication Critical patent/JP2009538824A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009502755A 2006-03-31 2006-10-04 精神疾患及び障害治療用アミリン及びアミリンアゴニスト Pending JP2009538824A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders
PCT/US2006/038919 WO2007114838A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (2)

Publication Number Publication Date
JP2009538824A true JP2009538824A (ja) 2009-11-12
JP2009538824A5 JP2009538824A5 (cg-RX-API-DMAC7.html) 2009-12-24

Family

ID=39876652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009502755A Pending JP2009538824A (ja) 2006-03-31 2006-10-04 精神疾患及び障害治療用アミリン及びアミリンアゴニスト

Country Status (7)

Country Link
EP (1) EP2010208A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009538824A (cg-RX-API-DMAC7.html)
KR (1) KR20080106950A (cg-RX-API-DMAC7.html)
AU (1) AU2006341375B2 (cg-RX-API-DMAC7.html)
CA (1) CA2647568A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008012666A (cg-RX-API-DMAC7.html)
WO (1) WO2007114838A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
WO2009043469A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of pneumadin as a therapeutic agent
JP2011525895A (ja) * 2008-06-25 2011-09-29 ノボ・ノルデイスク・エー/エス アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
JP2013511287A (ja) 2009-11-23 2013-04-04 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー ポリペプチド・コンジュゲート
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ES2108122T3 (es) * 1991-05-24 1997-12-16 Amylin Pharmaceuticals Inc Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
EP1750752A2 (en) * 2003-11-20 2007-02-14 Neuronova AB Compounds and methods for increasing neurogenesis
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
KR20080003849A (ko) * 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6012006982; MORLEY,J.E. et al: 'Effects of amylin on appetite regulation and memory' Can J Physiol Pharmacol Vol.73, No.7, 1995, p.1042-6 *
JPN6012006983; FLOOD,J.F. et al: 'Differential effects of amylin on memory processing using peripheral and central routes of administr' Peptides Vol.13, No.3, 1992, p.577-80 *
JPN6012006985; NEW薬理学 , 2002, p.289-296 *
JPN6013005917; メルクマニュアル第17版日本語版 , 1999, p.1521-1523,1569-1575 *
JPN6013005918; 今日の治療指針2002年版 , 2002, p.616-619 *

Also Published As

Publication number Publication date
CA2647568A1 (en) 2007-10-11
WO2007114838A1 (en) 2007-10-11
AU2006341375A1 (en) 2007-10-11
MX2008012666A (es) 2008-10-13
EP2010208A1 (en) 2009-01-07
AU2006341375B2 (en) 2013-03-21
KR20080106950A (ko) 2008-12-09
AU2006341375A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
JP5114381B2 (ja) 精神疾患および障害治療用アミリンおよびアミリンアゴニスト
JP5226628B2 (ja) 摂食行動の修正
JP6124565B2 (ja) 摂食行動の修正
US20080176804A1 (en) Methods for Affecting Body Composition
JP2010111694A6 (ja) 摂食行動の修正
WO2009049215A1 (en) Methods to reduce the effects of sleep deprivation
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
DE69733575T2 (de) Verfahren und mittel zur schmerzbehandlung
US20090181890A1 (en) Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
CN101208098A (zh) 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
JPH06510753A (ja) インスリン欠乏哺乳動物治療用のインスリンおよびアミリンを含有する組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091002

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120510

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120613

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130212